Analyst consensus rating
Aclaris Therapeutics Analyst Rating: Strong Buy
Direct answer
Aclaris Therapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.36.
Forecast evidence checked November 13, 2026.
Get free Aclaris Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.00
- Average price target
- $10.36
- High price target
- $16.00
- Low price target
- $4.00
- Low target gap
- 0%
- Target upside
- +159.1%
- High target gap
- +300%
- Target range width
- 300%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aclaris Therapeutics?
Aclaris Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $10.36.
How far are Aclaris Therapeutics's low and high targets from the recorded price?
The low target implies 0%, while the high target implies +300%.
How many analysts are included in Aclaris Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Aclaris Therapeutics's target upside or downside calculated?
The average target of $10.36 is divided by the recorded price of $4.00, then one is subtracted to produce +159.1%. This does not guarantee a future return.
When was Aclaris Therapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.